Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.1800
-0.1088 (-37.67%)
Feb 26, 2026, 1:49 PM EST
Avenue Therapeutics Employees
Avenue Therapeutics had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
$702,000
Profits / Employee
-$1,872,000
Market Cap
593.03K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | -2 | -50.00% |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 35 |
| International Stem Cell | 32 |
| Evofem Biosciences | 32 |
| CERo Therapeutics Holdings | 8 |
| Lipella Pharmaceuticals | 7 |
Avenue Therapeutics News
- 1 year ago - Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds - GlobeNewsWire